Improving Safety By Computerizing Outpatient Prescribing
|ClinicalTrials.gov Identifier: NCT00235027|
Recruitment Status : Completed
First Posted : October 10, 2005
Last Update Posted : July 21, 2015
|Condition or disease||Intervention/treatment|
|Impact of Electronic Prescribing on Medication Safety||Other: Adverse Drug Event Monitoring|
Specific Aim 1: Increase routine identification of outpatient adverse drug events (ADEs) through development of a computerized ADE detection monitor.
Specific Aim 2: Use basic computerized outpatient prescribing to reduce preventable ADEs in a diverse array of outpatient settings.
Specific Aim 3: Use advanced decision-support within computerized prescribing to reduce the frequency of preventable ADEs, medication errors, and potential ADEs.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||701 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Care Provider)|
|Official Title:||Improving Safety By Computerizing Outpatient Prescribing|
|Study Start Date :||August 2000|
|Primary Completion Date :||December 2010|
|Study Completion Date :||December 2010|
Experimental: Adverse Drug Event Monitoring
In this intervention arm, clinicians received medication safety alerts when they prescribed medications in the electronic medical record.
Other: Adverse Drug Event Monitoring
The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
No Intervention: Care as Usual
In this arm, clinicians did not receive the medication safety alerts.
- Preventable Adverse drug events [ Time Frame: 8/5/2004 - 1/5/2005 ]Data were electronically collected each time a physician entered a prescription that triggered an alert related to medication safety.
- Total adverse drug events, medication errors [ Time Frame: 1/15/2001 - 5/15/2001 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00235027
|United States, Indiana|
|Indianapolis, Indiana, United States|
|United States, Massachusetts|
|Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|Study Director:||Tejal K Gandhi, MD, MPH||Brigham and Women's Hospital|
|Principal Investigator:||David Bates, MD||Brigham and Women's Hospital|
|Study Director:||Marc Overhage, MD||Regenstrief Institute, Inc.|